Paper - WANFANG MED ONLINE

You Position: Home > Paper

Progress in the treatment of human papillomavirus infection

( views:405, downloads:333 )

Author:: No author available

Journal Title:: International Journal of Dermatology and Venereology

Issue:: 1

DOI:: 10.3760/cma.j.issn.1673-4173.2012.01.008

Key Word:: 人乳头瘤病毒;感染;治疗;Human papillomavirus;Infection;Therapy

Abstract： Human papillomavirus (HPV) is a double-stranded DNA virus.Some HPV subtypes can specifically infect the skin and mucous membranes of the anogenital region,and induce a spectrum of epithelial proliferative diseases ranging from benign warts to intraepithelial neoplasms.It is now recognized that persistent cervical infection with high risk HPV subtypes is a prerequisite for the occurrence of cervical cancer.The treatment of HPV infection mainly includes prophylactic vaccines,microbicides,topical immunomodulators,therapeutic vaccines,etc.This paper presents recent progress in the treatment of HPV infection.

Reference

[1]Brown DR,Alvarez FB,Chiacchierini LM,etc.A controlled trial of a human papillomavirus type 16 vaccine.[J].2002,347(21).
[2]Burgess M,Gu W,McMillan NA,etc.Inhibition of cervical cancer cell growth in vitro and in vivo with dual shRNAs.[J].2011,18(3).
[3]Day PM,Schiller JT,Johnson KM,etc.Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus[J].2009,83(5).
[4]Wu TC,Hung CF,Tsen SW,etc.Therapeutic human papillomavirus vaccines: current clinical trials and future directions.[J].2008,8(4).
[5]Richard A, Moore,Elmer B, Santos,Philip K, Nicholls,etc.Intraepithelial DNA immunisation with a plasmid encoding a codon optimised COPV E1 gene sequence, but not the wild-type gene sequence completely protects against mucosal challenge with infectious COPV in beagles.[J].2002,304(2).
[6]Ault KA.Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials.[J].2007,369(9576).
[7]Gilchrist AT,Pomfret TC,Gagnon JM Jr.Quadrivalent human papillomavirus (HPV) vaccine: a review of safety, efficacy, and pharmacoeconomics.[J].2011,36(1).
[8]Walboomers JM,Jacobs MV,Manos MM,etc.Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.[J].1999,189(1).
[9]E.V. ROSS,R. ROMERO,N. KOLLIAS,etc.Selectivity of protoporphyrin IX fluorescence for condylomata after topical application of 5‐aminolaevulinic acid: implications for photodynamic treatment[J].1997,137(5).
[10].Carrageenan is a potent inhibitor of papillomavirus infection.[J].2006,2(7).
[11]Donalisio M,Rusnati M,Civra A,etc.Identification of a dendrimeric heparan sulfate-binding peptide that inhibits infectivity of genital types of human papillomaviruses.[J].2010,54(10).
[12]Hiroyuki, Ochi,Kazunari, Kondo,Koji, Matsumoto,etc.Neutralizing antibodies against human papillomavirus types 16, 18, 31, 52, and 58 in serum samples from women in Japan with low-grade cervical intraepithelial neoplasia.[J].2008,15(10).
[13]Reyes-Gutierrez P,Alvarez-Salas LM.Cleavage of HPV-16 E6/E7 mRNA mediated by modified 10-23 deoxyribozymes[J].2009,19(3).
[14]Harper DM,Franco EL,Wheeler CM,etc.Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial.[J].2006,367(9518).
[15]Rusnati M,Landolfo S,Cappello P,etc.Sulfated K5 Escherichia coli polysaccharide derivatives as wide-range inhibitors of genital types of human papillomavirus.[J].2008,52(4).
[16]F XBosch,ALorincz,NMunoz,etc.The causal relation between human papillomavirus and cervical cancer[J].2002,55(4).
[17]Dymalla S,Scheffner M,Weber E,etc.A novel peptide motif binding to and blocking the intracellular activity of the human papillomavirus E6 oncoprotein.[J].2009,87(3).
[18]Rusnati M,Oreste P,Zoppetti G,etc.Biotechnological engineering of heparin/heparan sulphate: a novel area of multi-target drug discovery.[J].2005,11(19).
[19]Donnarumma M,Tufano MA,Grimaldi E,etc.5-aminolaevulinic acid and photodynamic therapy reduce HSV-1 replication in HaCat cells through an apoptosis-independent mechanism.[J].2008,24(5).
[20]Adam J. Donne,Lynne Hampson,Xiaotong T. He,etc.Cidofovir induces an increase in levels of low‐risk and high‐risk HPV E6[J].2009,31(7).
[21]McCarron PA,Donnelly RF,Woolfson AD,etc.Photosensitiser delivery for photodynamic therapy. Part 1: Topical carrier platforms.[J].2008,5(7).
[22]Barbara, Klencke,Mark, Matijevic,Robert G, Urban,etc.Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101.[J].2002,8(5).
[23]Reddy KVR,Talwar GP,Mitra D,etc.A novel polyherbal microbicide with inhibitory effect on bacterial, fungal and viral genital pathogens[J].2008,32(2).
[24]Christopher B, Buck,Diana V, Pastrana,Douglas R, Lowy,etc.Generation of HPV pseudovirions using transfection and their use in neutralization assays.[J].2005,119.
[25]Bosch, F. Xavier,de Sanjosé, Silvia.The epidemiology of human papillomavirus infection and cervical cancer.[J].2007,23(4).
[26]Wierzbicka M,Jackowska J,Bartochowska A,etc.Effectiveness of cidofovir intralesional treatment in recurrent respiratory papillomatosis.[J].2011,268(9).
[27]Ault KA,Malm C,Barr E,etc.Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial.[J].2005,6(5).
[28]Morrow DI,Garland MJ,McCarron PA,etc.Innovative drug delivery strategies for topical photodynamic therapy using porphyrin precursors.[J].2007,26(2).
[29]Asta, Juzeniene,Petras, Juzenas,Johan, Moan.Application of 5-aminolevulinic acid and its derivatives for photodynamic therapy in vitro and in vivo.[J].2010,635.